Feed MDWD
MD

MediWound Ltd.

MDWD · NASDAQ

$13.11 -3.32% (-$0.45)
1M -1.44%
Market Cap $176.1M
P/E Ratio -
Div. Yield -
ROE 47.24%
Piotroski F-Score Weak
1/9
Valuation
19 /100
Expensive
P/S 14.85x
P/B 4.94x
P/E N/A
Growth
22 /100
Declining
Rev. growth 13.82%
Book val. growth 58.71%
EPS growth N/A
Profitability
4 /100
Weak
Gross margin 15.46%
Net margin 170.10%
Op. margin 267.86%
Quality
2 /100
Poor
ROIC 70.36%
ROE 47.24%
ROA 28.07%
Debt
69 /100
Low
Debt/Equity 0.27x
Current ratio 2.32x
Int. coverage -18.64x
Stability
18 /100
Unstable
Beta 0.16x
Rev. volatility 19.11%
EPS volatility 209.25%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o MDWD
Online

O podjetju

MediWound Ltd. (MDWD) is a biotechnology company focused on the development of innovative therapeutic products for the treatment of skin injuries, burns, and other dermatological conditions. Their main product is an enzymatic medicinal preparation called NexoBrid®, which is used for the removal of burned tissue and promotes wound healing. MediWound Ltd. is known for its research and development of new treatment methods aimed at improving the treatment of patients with burns and other skin injuries. The company also offers additional therapeutic products and services for the healthcare sector. MediWound Ltd. (MDWD) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on the treatment of skin injuries and burns.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Ofer Gonen

Employees

121

Headquarters

Yavne

Prihajajoči dogodki

19 NOV.

Earnings

Upcoming earnings report

69d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.